# IGF-1 receptor (IGF1R)

Source: https://onco.cc/targets/igf1r/  
OnCo record `igf1r` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The IGF-1 receptor is a growth-factor receptor that many cancers use to survive; a decade of antibodies and kinase inhibitors against it failed in trials, a cautionary tale in oncology drug development.

## Summary

Insulin-like growth factor 1 receptor is a receptor tyrosine kinase closely related to the insulin receptor that promotes growth and survival through PI3K-AKT and MAPK signalling. Antibodies (ganitumab, figitumumab, dalotuzumab) and small molecules (linsitinib) were tested in lung, breast, pancreatic and Ewing sarcoma without meeting their endpoints, partly because of insulin receptor compensation and hyperglycaemia. The only approved IGF1R antibody, teprotumumab, treats thyroid eye disease rather than cancer.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: IGF1R
- Class: kinase
- Biology: A heterotetrameric receptor kinase activated by IGF-1 and IGF-2; hybrid receptors with the insulin receptor complicate selective blockade.
- Where found: Ewing sarcoma, breast, lung and pancreatic cancers (expressed); Most normal tissues at lower levels

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Insulin-like_growth_factor_1_receptor
- UniProt P08069: IGF1R: https://www.uniprot.org/uniprotkb/P08069/entry
- HGNC:5465 IGF1R: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5465
- ChEMBL target CHEMBL1957: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1957

## Connected records

- cancers: [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/igf1r.json